


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+0.23%
-1.87%
+0.90%
+1.26%
COGT
Cogent Biosciences I
$37.34
Strengths

Earnings are forecast to grow

Upgraded on attractively valued
COGT Price Performance
$37.86 (-1.37%)
$39.67 (-5.87%)
$14.13 (+164.26%)
$6.85 (+445.11%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Has a Strong balance sheet
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
COGT Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
COGT Street Sentiment is bullish and have positive views on the near-term outlook
COGT has Low risk level
Sentiments overview associated with events and the stock performance
Average key support and resistance price levels
Recent Upgrades and Downgrades
Dec 09, 2025
Reiterate
Hold
Needham
Nov 14, 2025
Reiterate
Buy
HC Wainwright & Co.
Nov 12, 2025
Reiterate
Neutral
Baird
Nov 11, 2025
Reiterate
Outperform
Leerink
Nov 05, 2025
Reiterate
Buy
HC Wainwright & Co.
What is COGT current stock price?
What are COGT stock strengths?
What is COGT Risk Level?
What is COGT market cap and volume?
What is COGT current Stock IQ?
Should I buy COGT stock right now?
Is COGT a Strong Buy right now?
What does a 'Strong Buy' rating mean for COGT?
What does a 'Strong Sell' rating mean for COGT?
What factors influence COGT's Stock IQ?
Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Recently Viewed
Most Trending
COGT
Cogent Biosciences I
Current Price
$37.34

COGT Price Performance
$37.86 (-1.37%)
$39.67 (-5.87%)
$14.13 (+164.26%)
$6.85 (+445.11%)
COGT Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Has a Strong balance sheet
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
COGT Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
COGT Street Sentiment is bullish and have positive views on the near-term outlook
COGT has Low risk level
Average key support and resistance price levels
Overall Wall Street Rating
COGT Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued
COGT Latest Analysis
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough. Key PointsFirst Turn Management acquired 824283 shares of Cogent Biosciences in the fourth quarter.
Tue Feb 17, 2026
Cogent Biosciences Stock Soars 346% in a Year but One Fund Just Sold Off $4.5 Million. Key PointsRock Springs Capital Management sold 159278 shares of Cogent Biosciences in the fourth quarter. the estimated trade size was $4.48 million based on quarterly average prices.
Tue Feb 17, 2026
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results. WALTHAM Mass. and BOULDER Colo. Feb. 17 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences Inc. (Nasdaq: COGT) a biotechnology company focused on developing precision therapies for genetically defined diseases today provided a business update and reported financial results for the fourth quarter and full year of 2025.
Tue Feb 17, 2026
Commit To Buy Cogent Biosciences At $25 Earn 17.2% Using Options. Investors considering a purchase of Cogent Biosciences Inc (Symbol: COGT) shares but cautious about paying the going market price of $36.59/share might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in pa
Thu Feb 5, 2026
Cogent Biosciences (COGT) Advances Bezuclastinib-Sunitinib Combination With Breakthrough Therapy Designation (BTD). Cogent Biosciences Inc. (NASDAQ:COGT) is one of the 11 Best Performing Stocks in the Last 12 Months. On January 26 2026 Cogent Biosciences Inc. (NASDAQ:COGT) announced a major milestone receiving a Breakthrough Therapy Designation (BTD) by the United States Food and Drug Administration. The designation came for bezuclastinib in combination with sunitinib for patients with Gastroint
Mon Feb 2, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
COGT Stock trends
COGT Stock performance
COGT Stock analysis
COGT investment strategies
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.